Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Advanced Solid Tumors · Agitation Associated with Alzheimer’s Disease

Bristol-Myers Squibb Australia

Bristol-Myers Squibb Australia Pty Ltd

Bristol-Myers Squibb Australia clinical programs — 93 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
PO Box 1080, Mount Waverley, Victoria 3149, Australia HQ
6 Employees
TGA registrant Type
Company details
Status
Public
HQ
PO Box 1080, Mount Waverley, Victoria 3149, Australia
Employees
6
Programs
93
Drugs
120
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Bristol-Myers Squibb Australia projects

93 ClinicalTrials.gov programs sponsored by Bristol-Myers Squibb Australia.

Bristol-Myers Squibb Australia has 93 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

93 programs

Clinical programs

Page 2 of 2

  1. IM047-050

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsing Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  2. IM101-863

    Bristol-Myers Squibb Australia Pty Ltd

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  3. Xanomeline and Trospium Chloride Capsules

    Bristol-Myers Squibb Australia Pty Ltd

    Schizophrenia

    phase 3 small molecule completed

    1 trial

  4. BMS-986517

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  5. BMS-986523, BMS-986523

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumor Malignancies

    phase 2 small molecule active

    1 trial

  6. CA001-044

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  7. CA001-050

    Bristol-Myers Squibb Australia Pty Ltd

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. CA011-023

    Bristol-Myers Squibb Australia Pty Ltd

    DIPSS-Intermediate or High Risk Myelofibrosis

    phase 2 small molecule active

    1 trial

  9. CA027-002

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  10. CA043-001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  11. CA0471009

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  12. CA082-1215

    Bristol-Myers Squibb Australia Pty Ltd

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  13. CA116-001

    Bristol-Myers Squibb Australia Pty Ltd

    Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    phase 2 small molecule active

    1 trial

  14. CA126-0015

    Bristol-Myers Squibb Australia Pty Ltd

    Oncology, NSCLC and CRC

    phase 2 small molecule active

    1 trial

  15. CA180-226

    Bristol-Myers Squibb Australia Pty Ltd

    Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib

    phase 2 small molecule active

    1 trial

  16. CA204-185

    Bristol-Myers Squibb Australia Pty Ltd

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  17. CA209-032

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors: 1) Triple Negative Breast Cancer (TNBC) 2) Gastric Cancer (GC) 3) Pancreatic Cancer (PC) 4) Small Cell Lung Cancer (SCLC). 5) Bladder Cancer (BC) 6) Ovarian Cancer (OC)

    phase 2 small molecule active

    1 trial

  18. CA209-142

    Bristol-Myers Squibb Australia Pty Ltd

    MSI Negative Colorectal Cancer, MSI Positive Colorectal Cancer

    phase 2 small molecule active

    1 trial

  19. CA209-1533

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  20. CA209-8TT

    Bristol-Myers Squibb Australia Pty Ltd

    Pan tumor

    phase 2 small molecule active

    1 trial

  21. CA224-020

    Bristol-Myers Squibb Australia Pty Ltd

    Neoplasms by site

    phase 2 small molecule active

    1 trial

  22. CA224-048

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  23. CA224-104

    Bristol-Myers Squibb Australia Pty Ltd

    Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  24. CA224-1044

    Bristol-Myers Squibb Australia Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  25. CA224-106

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced/metastatic hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  26. CA230-1019

    Bristol-Myers Squibb Australia Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule active

    1 trial

  27. CA2360001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  28. CA244-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  29. CA258-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Relapsed/Refractory Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  30. CA2660006

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or unresectable Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  31. CN008-0003

    Bristol-Myers Squibb Australia Pty Ltd

    Early Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  32. MRTX1719

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  33. Placebo for bms-986435-01

    Bristol-Myers Squibb Australia Pty Ltd

    Heart failure with preserved ejection fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  34. farletuzumab ecteribulin

    Bristol-Myers Squibb Australia Pty Ltd

    Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  35. A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  36. CA011-1010

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  37. CA111-001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 1 other active

    1 trial

  38. CA127-1027

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  39. CA235-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Acute Myeloid Leukemia and Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  40. CA240-0008

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  41. CA243-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    phase 1 other active

    1 trial

  42. CN0140003

    Bristol-Myers Squibb Australia Pty Ltd

    Neuropsychiatric indications and potentially other conditions

    phase 1 other active

    1 trial

  43. IM034-1000

    Bristol-Myers Squibb Australia Pty Ltd

    Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  44. IM060-0001

    Bristol-Myers Squibb Australia Pty Ltd

    Systemic Sclerosis, Idiopathic Inflammatory Myopathy, Rheumatoid Arthritis, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  45. IM011-1130

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Bristol-Myers Squibb Australia have?

93 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.